Profiles of gene transcription have begun to delineate the molecular basis of ovarian cancer, including distinctions between carcinomas of differing histology, tumor progression and patient outcome. However, the similarities and differences among the most commonly diagnosed noninvasive borderline (low malignant potential, LMP) lesions and invasive serous carcinomas of varying grade (G1, G2 and G3) have not yet been explored. Here, we used oligonucleotide arrays to profile the expression of 12 500 genes in a series of 57 predominantly stage III serous ovarian adenocarcinomas from 52 patients, eight with borderline tumors and 44 with adenocarcinomas of varying grade. Unsupervised and supervised analyses showed that LMP lesions were distinct from high-grade serous adenocarcinomas, as might be expected; however, well-differentiated (G1) invasive adenocarcinomas showed a strikingly similar profile to LMP tumors as compared to cancers with moderate (G2) or poor (G3) cellular differentiation, which were also highly similar. Comparative genomic hybridization of an independent cohort of five LMP and 63 invasive carcinomas of varying grade demonstrated LMP and G1 were again similar, exhibiting significantly less chromosomal aberration than G2/G3 carcinomas. A majority of LMP and G1 tumors were characterized by high levels of p21/WAF1, with concomitant expression of cell growth suppressors, gadd34 and BTG-2. In contrast, G2/G3 cancers were characterized by the expression of genes associated with the cell cycle and by STAT-1-, STAT-3/JAK-1/2-induced gene expression. The distinction between the LMP-G1 and G2-G3 groups of tumors was highly correlated to patient outcome (v 2 for equivalence of death rates ¼ 7.681189; P ¼ 0.0056, log-rank test). Our results are consistent with the recent demonstration of a poor differentiation molecular 'meta-signature' in human cancer, and underscore a number of cell-cycle-and STAT-associated targets that may prove useful as points of therapeutic intervention for those patients with aggressive disease.
Profiles of gene transcription have begun to delineate the molecular basis of ovarian cancer, including distinctions between carcinomas of differing histology, tumor progression and patient outcome. However, the similarities and differences among the most commonly diagnosed noninvasive borderline (low malignant potential, LMP) lesions and invasive serous carcinomas of varying grade (G1, G2 and G3) have not yet been explored. Here, we used oligonucleotide arrays to profile the expression of 12 500 genes in a series of 57 predominantly stage III serous ovarian adenocarcinomas from 52 patients, eight with borderline tumors and 44 with adenocarcinomas of varying grade. Unsupervised and supervised analyses showed that LMP lesions were distinct from high-grade serous adenocarcinomas, as might be expected; however, well-differentiated (G1) invasive adenocarcinomas showed a strikingly similar profile to LMP tumors as compared to cancers with moderate (G2) or poor (G3) cellular differentiation, which were also highly similar. Comparative genomic hybridization of an independent cohort of five LMP and 63 invasive carcinomas of varying grade demonstrated LMP and G1 were again similar, exhibiting significantly less chromosomal aberration than G2/G3 carcinomas. A majority of LMP and G1 tumors were characterized by high levels of p21/WAF1, with concomitant expression of cell growth suppressors, gadd34 and BTG-2. In contrast, G2/G3 cancers were characterized by the expression of genes associated with the cell cycle and by STAT-1-, STAT-3/JAK-1/2-induced gene expression. The distinction between the LMP-G1 and G2-G3 groups of tumors was highly correlated to patient outcome (v 2 for equivalence of death rates ¼ 7.681189;
Introduction
Cancer of the ovary accounts for the highest tumorrelated mortality among women diagnosed with gynecological malignancy (Berek et al., 2000) . Of the 40 100 new cases of ovarian cancer estimated by the American Cancer Society (ACS) in 2004, roughly 50% will die from their disease. The high ratio of death-to-incidence for patients with ovarian carcinoma is largely due to late-stage diagnosis, at a time when the disease has typically spread beyond the ovary. Whereas the 5-year survival rate for patients with stage I disease, which is confined to the ovary, is >90%, survival over the same period of time for patients diagnosed with stage III or IV disease is o20% (Berek et al., 2000) . Late-stage diagnosis of ovarian carcinomas can be attributed to the fact that the disease is relatively 'asymptomatic' in its early stages, and that the symptoms of late-stage disease, such as abdominal discomfort, weight loss, diarrhea or constipation, vaginal bleeding and shortness of breath, are nonspecific complaints (Berek et al., 2000) . Serous adenocarcinomas, which account for B80% of all ovarian cancer cases, are thought to arise from the single epithelial cell layer that lines the ovary or from invagination cysts lined with these cells within the ovary (Auersperg et al., 2002) . However, it is essentially unclear as to whether ovarian carcinomas evolve through a continuum of histologically progressive dysplasia and neoplasia, as is the case for other adenocarcinomas, such as those that arise in the colorectum (Hamilton, 1992) .
Approximately 10-15% of all serous diagnoses are classified as tumors of low malignant potential (LMP), which are well differentiated and mostly noninvasive (Berek et al., 2000) . Roughly 65-70% of serous LMP tumors are diagnosed at stage I, whereas those with extraovarian spread occur in the remaining 30-35% of cases (stages II-IV). Treatment of stage I LMP tumors is uniformly surgical resection, whereas treatment of advanced-stage lesions can include standard cytotoxic regimes. The value of adjuvant therapy in this setting is currently unclear (Gershenson, 2002) . The prognosis of patients with LMP tumors is largely determined by whether peritoneal implants are present at the time of diagnosis, and if these implants are invasive. Peritoneal implants with evidence of invasion (termed 'evolutive invasive disease') are significantly more likely to progress over 5 years (30%), as compared to patients with no evidence of peritoneal invasion (2%) (Morice et al., 2003) . These observations have led some to suggest that the term LMP is obsolete, since invasive LMP tumors should be considered well-differentiated invasive serous carcinoma (Seidman et al., 2002; Seidman and Kurman, 2003) .
There is nonetheless ongoing debate as to whether LMP tumors are precursors of common higher-grade serous carcinomas. The lines of evidence in favor of this are the generally younger diagnosis of patients with LMP (mid-40s versus 70 years) (Berek et al., 2000) , suggesting that these might precede more aggressive disease, and the fact that 20-30% of patients with advanced-stage (II-IV) LMP tumors relapse following surgery, typically with a low-grade invasive carcinoma (Gershenson, 2002) . Recent molecular studies, however, suggest that LMP tumors may be unrelated to invasive serous adenocarcinoma. Among the key findings in support of this are high frequencies of ras pathway mutations (codon 12 and 13 mutations in Ki-ras or the v599e mutation in b-raf) in LMP tumors, which are infrequent in serous carcinomas (Singer et al., 2003) , and the anticorrelated status of p53, which is typically wild type in LMP tumors and mutated at high frequency in carcinoma (Caduff et al., 1999; Chan et al., 2000) . A recent study of p53 mutations in paired advanced-stage LMP and low-grade serous carcinomas from the same patient (classified as relapsed patients) found different p53 mutations in 7/8 patients, as well as an absence of p53 mutations in the secondary tumor compared with the advance LMP tumor (Ortiz et al., 2001) , strongly suggesting a divergent origin of LMP and invasive carcinoma.
Examination of genome-scale transcript levels in ovarian carcinomas has led to the identification of a number of consistently deregulated genes, such as the whey acidic protein, HE4, and osteopontin, both of which have shown promise as putative disease biomarkers Wang et al., 1999; Welsh et al., 2001a; Kim et al., 2002; Hellstrom et al., 2003) . The same approach has begun to delineate the molecular distinction between carcinomas of differing histology (clear-cell, endometrioid and serous carcinomas (Schwartz et al., 2002) ), patient outcome (Collins et al., 2004) and, to a lesser extent, molecular signatures of cellular differentiation (Jazaeri et al., 2003) . However, the inter-relationship between well-differentiated, noninvasive borderline tumors (LMP) and invasive carcinomas of varying grade have not been explored on this scale. Thus, the extent to which LMP lesions differ from normal tissue in comparison to invasive cancers is unclear. Similarly, the differences between LMP tumors and their invasive counterparts are also unclear.
To address these questions, we profiled the expression of 12 500 genes on oligonucleotide arrays in a series of 57 tumors: eight from patients with borderline tumors (stages I-III) and 49 from patients with predominantly stage III/IV serous adenocarcinoma of varying grade. We report a striking molecular similarity among LMP tumors and well-differentiated (G1) adenocarcinomas, as well as a predictable similarly among moderately (G2) and poorly differentiated (G3) carcinomas. These molecular characteristics were reflected by a differential prognosis among patients (i.e. LMP-G1 versus G2-G3), demonstrating clinical utility of the analyses. Several of the differentially expressed genes point to putative targets that can be exploited therapeutically. Finally, our data support the hypothesis that noninvasive LMP and a substantial subset of invasive G1 carcinomas may evolve independently compared to adenocarcinomas with moderate and poor cellular differentiation.
Results
Tumors of LMP are molecularly distinct from high-grade invasive adenocarcinomas, but highly similar to low-grade invasive malignancy RNA from 57 tumor samples was hybridized to oligonucleotide arrays containing probe-sets for B12 000 genes. These samples represented tumors resected from 52 patients: eight unique samples of borderline malignancy from eight patients, and 49 invasive adenocarcinomas from 44 patients. The invasive carcinomas were predominantly advanced stage (III-IV; the most common stages at the time of presentation), and diagnosed with low (G1; n ¼ 7), moderate (G2; n ¼ 17) or high (G3) grade (n ¼ 20). The primary data from the microarray hybridizations were filtered to exclude genes with low and invariant expression, resulting in a subset of 5825 probe-sets (B5000 unique genes).
We preformed unsupervised (agglomerative) clustering to assess the extent of sample inter-relationships, allowing gene expression levels to drive the grouping of samples (Figure 1a ). This analysis identified several groups, most notably a conspicuous demarcation between LMP and several of the well-differentiated (G1) tumors from moderately (G2) and poorly (G3) differentiated tumors. Of the 15 LMP-G1 tumors that we profiled (eight LMP, seven G1), 12/15 of the tumors consistently grouped together following multiple iterations of clustering with different numbers of genes (data Figure 1) , consistent with our previous observation that samples with high expression of these genes are typically well differentiated or of LMP (Welsh et al., 2001b) . Another group of samples, delineated by the cluster immediately adjacent to the LMP/G1 cluster, included tumors of varying differentiation, including one of the LMP lesions and two of the G1 lesions; however, this coclustering appeared to be driven in part by the expression of genes encoding extracellular matrix proteins and genes whose expression is typically associated with stromal cells (Supplementary Figure 1) . Whether these genes are expressed by stromal cells or the tumor cells, however, is debatable, as many of the same genes are highly expressed in tumor-derived short-term cultures (Matei et al., 2002 ). An assessment of the clusters for association with tumor stage revealed that all of the stage I (n ¼ 3) and stage II (n ¼ 3) tumors were encompassed by the 12 samples in the LMP-G1 cluster (far right of the dendrogram, Figure 1a ). Although this might suggest that stage is a determining factor in guiding the association of samples within this group, it should be noted that 6/12 tumors were stage III carcinomas, supporting the notion that many of the well-differentiated tumors are established malignancies.
To assess whether the association of LMP and lowgrade malignancy observed with unsupervised analysis could be statistically verified, we performed a supervised learning analysis using a K nearest neighbors (KNN) method. A series of three different classification models was set up to test this hypothesis using KNN: (1) LMP þ G1 versus G2 and G3, (2) LMP þ G1 versus G2 þ G3 and (3) LMP þ G1 þ G2 versus G3 (Table 1) . Each model was assessed by leave-one-out crossvalidation, whereby a single sample is withheld from the sample set, a predictor generated and used to predict the class of the withheld sample. For each of these models, we evaluated the predictive power of 1-20 genes (in increments of 1) and 30-100 genes (in increments of 10). Among the three models that we evaluated, we found that the most accurate prediction was generated by a model in which LMP and G1 tumors were grouped together, as expected, but where G2/G3 cancers were also grouped together (Table 1) . Overall, an 18-or 80-gene model predicted class memberships with 95% accuracy (i.e. 54/57 correct predictions). The errors were generated by two G1 lesions, which displayed a G2-G3-like profile (B1 and F14, Figure 1b) , and one of the G2-G3 tumors that exhibited an LMP-G1-like profile (G19, Figure 1b ). The significance of this classification model was assessed by performing random permutations of the sample names 1000 times. In no case did we observe classification accuracies as high as 95% (Po0.001).
As the group labels of the samples used in the supervised KNN analysis above were delineated through agglomerative clustering and could thus bias the analysis toward expression-based differences (rather than known labels, such as tumor grade), we also evaluated sample inter-relationships using significance of microarrays analysis (SAM) (Tusher et al., 2001) . The hypothesis tested was that there should be few if any genes that could reproducibly distinguish LMP and G1 or G2 and G3 tumors after multiple rounds of permutation, where the group labels are iteratively scrambled. In the case of LMP versus G1, we identified a maximum of nine genes with a false discovery rate (FDR) of 22%. For G2 versus G3, we identified a maximum of 21 genes with an FDR or 4%. In sharp contrast, we identified a series of 156 genes with an FDR of o0.5% in the LMP-G1 versus G2-G3 comparison (333 genes at 1%), strongly supporting the molecular division among these groups of tumors (Supplementary Figure 2) .
Comparative genomic hybridization (CGH) analysis demonstrates increased chromosomal aberration among G2 and G3 carcinomas
We next used CGH to ask whether the similarities among expressed genes were reflected at a genomic level. CGH was performed on an independent set of 68 serous tumors, diagnosed as LMP (n ¼ 5), G1 (n ¼ 2), G2 (n ¼ 28) and G3 (n ¼ 33). A measure of genomic aberrations termed ANCA (Average Number of Copy Alterations, see Materials and methods) was used to categorize tumors. This score takes into account the number of chromosomal gains and losses on each chromosome in each tumor, adds the total number of aberrations and then computes an 'average' number of changes genome-wide (Kiechle et al., 2001) . The ANCA score for LMP and G1 tumors was found to be 2.0, whereas the ANCA values for G2 and G3 tumors were 11.7 and 10.5, respectively, delineating a significantly higher degree of genomic instability in G2-G3 tumors and, again, suggesting a molecular similarity among LMP and G1 tumors ( Figure 2 ).
Genes associated with the cell cycle and JAK/STAT signaling distinguishes LMP and G1 from G2 and G3 carcinomas
The genes that correlated best with the distinction between the LMP-G1 and G2-G3 classes are instructive ( Table 2 ). The LMP-G1 group of tumors was characterized by the near-uniform expression of genes such as MUC5B, c-fos and p21/WAF-1 (CDKN1A) (Figure 1b ). Although high p21 expression has previously been reported in LMP tumors (Palazzo et al., 2000) , we were surprised to see high expression of CDKN1A in G1 tumors, which suggested decreased cellular growth capacity of these invasive carcinomas. Using Euclidean distance as a measure of similarity, we searched for genes whose expression was highly correlated with CDKN1A ( Figure 3a ). This analysis identified genes such as BTG-2 and gadd34, both of which are capable of suppressing tumor cell proliferation (Rouault et al., 1996; Hollander et al., 2003; Kuo et al., 2003; Yagi et al., 2003) , and are also transactivated by p53. The expression of MUC5B may indicate a mucinous phenocopy, consistent with a high rate of Ki-ras mutations in both mucinous ovarian adenocarcinomas (Gemignani et al., 2003) and in LMP tumors (Caduff et al., 1999) .
The G2-G3 tumor group was characterized by the near-uniform overexpression of genes linked to the cell cycle (e.g. cdc20, cyclin B), markers of cell proliferation (e.g. Ki-67) and genes mediating JAK/STAT signaling (e.g. STAT-1, STAT-3, JAK-1, MxB). One of the strongest predictors of the G2-G3 group was UbcH10, a cell-cycle-associated ubiquitin ligase gene for which we (Wagner et al., 2004) and others (Okamoto et al., 2003) have previously provided evidence for its oncogenic role in multiple human tumors. Using UbcH10 as a seed gene, we observed a remarkable, near-uniform categorization of G2-G3 tumors based on high expression of multiple cell-cycle-associated genes ( Figure 3b ). The genes most highly correlated with UbcH10 included topoisomerase IIa, the target of the topoisomerase inhibitor, etoposide (Capranico et al., 1999) , as well as fatty acid synthase (FASN), which is currently being exploited as a therapeutic target in ovarian and other carcinomas (see Discussion). We performed a similar correlation analysis with the interferon transcription factor, STAT-1, which returned a set of genes activated by STAT-1 (e.g. MxB, IFI-30, IFI-35), as well as multiple probe-sets representing JAK-1, STAT-3 and STAT-1 itself ( Figure 3c ).
We confirmed the results of the microarray-based analyses in part by immunohistochemistry, using antibodies against p21/WAF-1 and Ki-67 as representative proteins of each group. The antibodies were screened on tissue microarrays (TMAs) containing 353 tissue cores from 120 ovarian carcinoma cases, 72 of which were serous papillary carcinomas. For six of these patients, specimens lacking tumor tissue were also available. In addition, six specimens of normal ovary derived from individuals who were not diagnosed with ovarian cancer were stained in the same experiment. Using a score based on intensity (0-3) Â number of positive cells (0-100%), p21 staining was highly similar in LMP and G1 lesions (208 and 194, respectively) as compared to G2 and G3 lesions (both 80). For Ki-67, a more gradual increase was observed, from 0 and 6 in LMP and G1 lesions to 11 and 14 in G2 and G3 carcinomas (Figure 4a) .
Based on the striking upregulation of STAT-1 and STAT-1 target genes (e.g. IFI-30, IFI-44, IFI-15k, MX1; Figure 3c ), and the potential therapeutic implication of their elevated expression, we performed semiquantitative RT-PCR to examine transcription of these genes in a subset of tumors (two each of LMP, G1, G2 and G3 tumors). In addition, we chose other genes that exhibited the same pattern of G2-G3 overexpression, cdc20 and UbcH10, and genes that showed the opposing pattern (i.e. high in LMP-G1), CIRP and c-fos, for RT-PCR to further validate the array data. As shown in Figure 4b , the relative transcription of all of these genes paralleled the hybridization intensity detected on the arrays.
Finally, we queried the expression of a set of 69 genes that have recently been reported as a 'meta-signature' of poor differentiation in human cancers (Rhodes et al., 2004) , notably those arising in the colon, lung, ovary, bladder, breast, prostate and brain (glioma). Of the 69 genes reported, 67 could be identified in our data set, several of which overlapped with the G2/G3 signature reported here. These 67 genes were used to cluster all of the 57 tumor samples. Two clusters emerged from the analysis, one containing 21 (cluster 1) tumors and the other containing 36 tumors (cluster 2). Notably, cluster 1 included all of the eight LMP tumors, 5/7 G1, seven G2 and one G3 carcinomas. Cluster 2 included all but one of the 21 G3 carcinomas, nine G2 and two G1 carcinomas (Supplementary Figure 3) . Notably, the most closely related 10 samples in cluster 1 were exclusively LMP or G1 carcinomas. These data again reinforce the consistency of the molecular signatures underlying tumor grade, and also highlights the possibility of G2 as intermediates between G1 and G3 carcinomas.
LMP tumors exhibit extensive differential gene expression when compared to normal tissue
The results presented above demonstrate a clear delineation between LMP-G1 and G2-G3 tumors. However, given that LMP tumors are typically noninvasive, whereas adenocarcinomas are, we next compared the gene expression profiles of LMP and high-grade tumors to normal ovarian tissue, to identify those genes that may yield mechanistic insight into their different phenotypes.
For this analysis, we focused on LMP and poorly (G3) differentiated invasive adenocarcinomas only, as these represent the extremes for comparative purposes. were subjected to agglomerative clustering using Cluster (Eisen et al., 1998) (average linkage, correlation uncentered) and visualized using Treeview (Eisen et al., 1998) . The dendrogram represents the relative similarity among samples; those with a high degree of relatedness are grouped closely together (e.g. F29, F29B, F29A); dissimilar samples are separated by a hierarchical structure representing the relative distance between samples. Samples of differing grade are color coded: yellow ¼ LMP; green ¼ G1; purple ¼ G2 and red ¼ G3. Multiple tissue samples resected from the same patient are highlighted by the boxes underneath the dendrogram. With one exception (F1-, F1A), all of the independently resected samples were found to be highly similar. The three samples that were consistently misclassified, B1, F14 and G19 (see Figure 1) , are highlighted by the purple circles. (b) Top 100 genes that best correlate with the LMP-invasive distinction were identified by a signal-to-noise (S2N) metric (Armstrong et al., 2002) . Each column represents a single tumor sample (denoted by the groups LMP, G1, G2 and G3) and each row represents the relative expression of a single gene. The expression of each transcript is normalized to a mean of zero, and its deviation from the mean is represented by the color spectrum, red signifying relative overexpression and blue signifying relative underexpression. The G1 carcinomas, which exhibited striking similarity to the LMP tumors, are highlighted by the black arrowhead. Several of the genes with near-uniform relative under-or overexpression in LMP tumors are depicted to the right of the figure We first compared G3 tumors to four samples of normal tissue (Welsh et al., 2001b) based on a combination of fold-change (>2o0.5) and paired t-test (Po0.001), identifying 824 genes (693 and 131 with elevated and decreased expression, respectively). Comparison of LMP lesions to normal tissues identified 1026 genes (740 and 286 with elevated and decreased expression, respectively), of which 448 were common to both sets of tests (358 elevated and 90 decreased). Many of the genes common to both analyses have been reported in late-stage,
Molecular analysis of serous ovarian carcinoma I Meinhold-Heerlein et al invasive ovarian carcinomas in multiple studies (reviewed in Hampton, 2003) . These included MMP-7, GA733-2, mesothelin, CD9, CD24, KRT8, KRT18 and HE4. Also, while cell-cycle-associated genes, such as cyclin B1, were highly expressed in G3 carcinomas, they were also surprisingly elevated in LMP tumors as compared to normal tissue, although significantly less so than in G3 tumors (13-versus 44-fold, respectively). Likewise, we noted progressive increases in the expression of other genes, such as IGF-II (sevenfold in LMP, 30-fold in G3). The genes elevated in G3, but not in LMP tumors, were predominantly cell-cycle associated, as predicted by the supervised analysis.
We performed a similar analysis on the genes decreased in both G3 and LMP tumors. Many genes were identified, including p57/kip2, which have been described as downregulated in several types of cancer, and for which loss of expression is associated with transformation (Watanabe et al., 1998; Nijjar et al., 1999) . 
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Finally, we performed immunohistochemistry with antibodies against five of the proteins apparently upregulated in both LMP and G3 carcinomas compared to normal epithelia, Ep-CAM/GA733-2, CD24, MMP-7, MUC-1 and S100A2, on the same TMAs described above (Supplementary Figure 4a) . The results of the TMA analyses were largely consistent with gene expression measurements. The mean immunostaining scores were higher in carcinomas compared to the normal surface epithelium for MMP-7 (P ¼ 0.009), S100A2 (P ¼ 0.03) and MUC-1 (NS) (Supplementary  Figure 4b) . Conversely, we found no statistically significant differences in CD24 and EpCAM protein levels between normal epithelia and carcinomas, although there was a trend toward increased EpCAM staining in carcinomas (Supplementary Figure 4b) . When clustered into two groups based on histological grading, CD24 and EpCAM protein levels were significantly elevated in high-grade carcinomas compared to LMP and low-grade carcinomas (P ¼ 0.004; P ¼ 0.03, respectively). EpCAM protein expression has been reported as increased in carcinomas compared to normal tissues, consistent with the trend noted here; however, the use of different antibodies precludes a direct comparison (Kim et al., 2003) . Overexpression of both EpCAM and CD24 has been shown by RT-PCR in other studies, consistent with our data here (Santin et al., 2004) . Thus, the results of the CD24 IHC suggest either that mRNA overexpression is not reflected as higher levels of protein or that other as yet undefined technical factors preclude detection of differential protein expression.
In aggregate, the results of the microarray and IHC analyses demonstrate that although LMP tumors are clearly and predictably distinct from higher-grade carcinomas, they are also substantially distinct from normal ovarian epithelia, sharing many of the molecular features of invasive carcinomas.
The LMP-G1 and G2-G3 molecular groups distinguish patient outcome
The molecular similarities between LMP-G1 and G2-G3 were reflected in the overall survival (OS) of patients in this cohort ( Figure 5 ). Long-term outcome data were available for 29 of the 52 patients whose tumors were profiled in this study (average OS ¼ 50 months). As individual groups (i.e. LMP, G1, G2 and G3), the outcome of the patients suggested a strong similarity between LMP and G1, as well as G2 and G3 tumors (albeit that LMP and G1 tumors are treated differently); when combined, the OS between the two groups was significantly different (P ¼ 0.0057, log-rank (Peto); P ¼ 0.0102, generalized Wilcoxon (Peto-Prentice)).
Discussion
Using gene expression profiling and CGH, we demonstrate that noninvasive borderline ovarian serous tumors (LMP) are molecularly distinct from moderate and high-grade serous carcinomas, a distinction that was, in part, expected based on studies of p53 and Ki-ras gene mutation (Caduff et al., 1999; Chan et al., 2000; Ortiz et al., 2001; Singer et al., 2003) . However, a prominent finding was the high degree of similarity among LMP tumors and many of the G1 carcinomas, as well as the similarity among moderate and higher-grade carcinomas. The LMP-G1/G2-G3 distinction was statistically predictable by supervised classification and mirrored by a significantly lower level of genomic instability and superior outcome of G1 carcinomas and LMP tumors compared to G2-G3 carcinomas. Based on the array data, the LMP-G1/G2-G3 distinction was predominantly driven by the aberrant expression of genes associated with the cell cycle and genes encoding JAK/STAT proteins and their downstream targets. A strong inverse correlation was observed between high expression of CDKN1A (p21/WAF-1) in LMP-G1 tumors and high expression of Ki-67 mRNA in G2-G3 carcinomas. Immunohistochemical staining with MAbs is strongly correlated with grade, and high expression of Ki-67 protein has been associated with shorter progression-free survival and OS (Henriksen et al., 1994; Marx et al., 1997; Korkolopoulou et al., 2002) . In one study, no appreciable difference was found in the relative intensity of Ki-67 staining among LMP and G1 tumors (Terlikowski et al., 1999) , consistent with our observation that LMPs and a majority of G1 carcinomas do not express detectable levels of Ki-67, either by array profiling of by immunostaining with Ki-67 antibodies. Conversely, CDKN1A mRNA is weakly expressed or absent in G2-G3 carcinomas and low or absent levels of this protein have been correlated with high-grade, advanced FIGO stage, primary residual tumor and poor OS. Low expression is also inversely correlated with high proliferative capacity and p53 positivity (Anttila et al., 1999; Palazzo et al., 2000; Vassilopoulos et al., 2003) .
The aberrant expression of cell-cycle-associated genes in G2-G3 carcinomas is not a novel observation, and not unexpected in the context of previous work, which has documented upregulation of several cell-cycle genes in ovarian carcinoma, such as polo-like kinase-1 (Takai et al., 2001; Weichert et al., 2004) , cdc25a and cdc25b (Broggini et al., 2000) , and their correlation with grade/stage and survival, respectively. However, the predictive power of large-scale analyses, such as that presented here, underscores the potential value of being able to monitor thousands of genes across different histologies and grades. Jazaeri et al. (2003) have recently shown that a major distinction between G1 and G3 carcinomas can be attributed to deregulated cell-cycle gene expression. Further, they show that a disproportionate number of these genes map to 20q13, a region of frequent chromosomal amplification in human tumors. Based on these data, the authors suggest that welldifferentiated serous carcinomas evolve toward a more poorly differentiated phenotype via 20q amplification, leading to wholesale deregulation of the cell-cycle machinery. Although plausible, it should be noted that patients do present with well-differentiated stage III/IV carcinomas, existing as substantially developed malignancy. Thus, while the potential for evolution to a more poorly differentiated lesion exists, it is not a requisite and does not imply a common linear evolution from G1 through G2 and G3. An alternative hypothesis is that LMP tumors and G1 carcinomas evolve independently from poorly differentiated malignancy (discussed in Shih Ie and Kurman, 2004) . This notion is supported by several lines of evidence. Genetically, analyses of allelic imbalances in serous LMP, micropapillary serous tumors and carcinomas of varying grade (loss of heterozygosity) suggests two distinct evolutionary pathways -one that primarily involves imbalances on several specific chromosomes (5p, 8q, 18q, 22q and Xp) and leads to borderline serous tumors or low-grade carcinomas and another that involves extensive chromosomal aberration, even in early lesions, which ultimately leads to the emergence of high-grade, late-stage tumors (Singer et al., 2002) . These observations are ratified by CGH analyses of low-grade carcinomas, which typically demonstrate diploid karyotypes, consistent with the CGH data reported here (Iwabuchi et al., 1995; Kiechle et al., 2001) . Clinically, patients with a relapsed ovarian malignancy subsequent to resection of an LMP tumor typically present with well-differentiated carcinomas, rather than lesions with poor differentiation (Gershenson, 2002) . Molecularly, analyses of Ki-ras (codons 12 and 13) and b-raf (v599e) sequences demonstrate a high frequency of ras pathway mutations (61-68%) in LMP and low-grade tumors, which are not detected in conventional adenocarcinomas (Singer et al., 2003) . Thus, the spectrum of genetic alterations reported in the literature, such as mutations in p53, Ki-ras, and chromosomal losses and gains, are quite different among G1 and G2-G3 tumors, although G2 has often been considered more intermediate or even G1-like in some studies.
Although cell-cycle deregulation is a hallmark feature of human cancer (Hanahan and Weinberg, 2000) , the tight association of cell-cycle deregulation specifically with tumor grade in epithelial carcinomas in general is only recently garnering attention, mostly because of large-scale expression profiling studies. These observations have very recently been reduced to a 'metasignature' of cancer cell differentiation, identified G2-G3 (n=16) Figure 5 Histological grade is correlated with patient outcome. Kaplan-Meier curves were generated from 25 patients whose outcome was followed over an average period of 50 months. Patients were stratified based on LMP, G1, G2 and G3 groupings (top) or on the combination of patients with LMP-G1 and G2-G3. X-axis, survival probability; Y-axis; OS (months). Censored cases are indicated by the vertical bars through the combined analysis of multiple types of human cancers. A subset of 69 genes identified across seven tumor types (including ovary) was shown to reliably predict poor differentiation in at least five of these cancer types, including ovary (P ¼ 0.005). Accordingly, we have shown that 67/69 of these genes are sufficient to separate well and poorly differentiated tumors by agglomerative clustering. A major question that arises from these analyses is the mechanistic basis for wholesale cell-cycle deregulation.
A second class of genes, characterized by the expression of STAT-1, JAK-1 and STAT-3, was also upregulated in G2-G3 carcinomas. The JAK/STAT pathway transduces a number of cytokine and growth factor signals, including interferons, via activation of the JAK kinases, which phosphorylate STAT factors, leading to STAT translocation to the nucleus and induction of target gene transcription, which includes STAT proteins themselves (Liu et al., 1998) . The significance of JAK/STAT induction (and downstream target gene transcription) in ovarian malignancy is beginning to emerge. Constitutive activation of STAT-3 is reported in high-grade ovarian carcinomas and has been shown to promote cell migration, physically localizing to focal adhesions in association with phospho-FAK and phospho-paxillin in SKOV-3 cells. Pharmacologic inhibition of JAK-2 with AG490, a small molecule JAK-2-specific inhibitor, currently in late preclinical development (Luo and Laaja, 2004) , decreases migratory potential, consistent with a direct role of STAT-3/JAK-2 signaling. Notably, the expression of STATs, particularly the STAT-1 gene, in multiple data sets within the ONCOMINE database (Rhodes et al., 2004) is notably increased (e.g. in high-grade breast, bladder and ovarian carcinomas, among others), suggesting that aberration of STAT-1-mediated signaling (if overexpression is functionally relevant) may contribute to malignant development.
LMP tumors and many of the G1 carcinomas expressed genes that are suggestive of growth arrest and terminal differentiation (i.e. CDKN1A, gadd34 and BTG-2). This hypothesis is supported by the observation that differentiation of surface colorectal epithelial layers from basal crypt cells is mediated by p21/WAF-1, which in turn induces high expression of several gadd genes (van de Wetering et al., 2002) . The biological significance of these particular genes in LMP-G1 tumors is further supported by a report showing that increased gadd34 expression, or ectopic expression of gadd34, leads to increased p53 phosphorylation at Ser15 and subsequent upregulation of p21/WAF-1 (Yagi et al., 2003) . Paradoxically, LMP tumors and G1 carcinomas are often diagnosed at late stages (i.e. III/IV), particularly in younger women. Therefore, these tumors have the capacity to grow, albeit at undefined rates, to substantial physical size in the presence of genetically defined growth suppressing gene expression.
Analysis of the cell-cycle-associated genes whose expression was elevated in G2-G3 carcinomas reveals several putative targets for therapeutic intervention, both well known and more recently described. An example of the former is topoisomerase IIa, the target of the topoisomerase inhibitor, etoposide (Capranico et al., 1999) , which is gaining support as second-line treatment of patients who fail first-line therapy, or relapse following initially successful treatment (Muggia and Lu, 2003) . An example of the latter is FASN. Expression of FASN has been associated with a typically aggressive disease course in the breast (Alo et al., 1996) , prostate (Shurbaji et al., 1996) and ovarian carcinomas (Gansler et al., 1997) . Although associated with the cell cycle in rapidly dividing cells (Pizer et al., 1998b) , natural (cerulenin) and synthetic (C75) inhibitors of FASN lead to tumor cell-selective apoptosis, leaving normal cells relatively unaffected (Pizer et al., 1996a (Pizer et al., , b, 1998a . Given the correlation with FASN expression and aggressive disease course here, FASN protein may be an ideal target in late-stage, higher-grade serous ovarian carcinomas. In this regard, fragments of the FASN protein have been detected in the sera of patients with ovarian and other carcinomas, providing a mechanism to identify those patients that would most benefit from FASN-directed therapy (Wang et al., 2001a, b) . Proofof-concept that FASN is a viable target is provided by the preclinical efficacy of the synthetic FASN inhibitor, C75, in NIH OVCAR4 cells implanted as s.c. xenografts in immunocompromised mice (Pizer et al., 1996b) .
In summary, the profiles of gene expression in stage III/IV serous ovarian tumors of varying grade and malignant potential demonstrate a striking molecular similarity among LMP lesions and invasive, welldifferentiated carcinomas. Our data also show a lack of separation between moderately and poorly differentiated invasive serous adenocarcinomas and, in fact, suggest that they form a single molecular group characterized by increased expression of cell-cycle genes. Notably, these profiles, if substantiated in larger data sets, which might form the basis of patient stratification indicating the differential treatment of well-differentiated and less well-differentiated tumors. Higher-grade carcinomas (i.e. G2 and G3), for example, may benefit from the emergence of molecularly targeted agents being developed against the JAK/STAT pathways, the FASN protein, as well as inhibitors of the ubiquitin ligase machinery (e.g. UbcH10). In the near-term, highergrade tumors may also benefit from treatment with wellestablished cytotoxics, such as etoposide, which are more selective for tumors with a high proliferative index.
Materials and methods

Tissue samples
For oligonucleotide microarray analysis, fresh-frozen samples of 57 tumors were obtained from 52 patients undergoing surgery for ovarian carcinoma at the University Hospital of Freiburg (n ¼ 28), the University Hospital Charite, Berlin, Germany (n ¼ 10) and at several US hospitals (collected under the auspices of the Co-operative Human Tissue Network (CHTN) (n ¼ 14), Midwestern Division Columbus, OH, USA). For several patients at the University of Freiburg, we obtained multiple samples, typically from one or more ovaries and the peritoneal cavity. Patient details, including tumor number, location, grade and stage, are tabulated in Supplementary  Table 1 (Table S1 ). For CGH, fresh-frozen samples of 68 serous tumors were obtained from 68 patients undergoing surgery for ovarian carcinoma at the University Hospital of Schleswig-Holstein, Campus Kiel, Germany. Institutional review board approvals were granted before accession of the tissues. The histological characteristics of each sample were assessed on formalin-fixed and paraffin-embedded H&E sections, and approximately similar areas of the frozen tumor samples were used for RNA and DNA extraction. Most specimens contained 80-90% tumor cells, while no specimen contained less than 60% tumor cells. Three of four normal tissue samples were obtained from the CHTN as described previously (Welsh et al., 2001b) . One of the normal samples (HOVR) was purchased from a commercial source (Biochain Institute, Hayward, CA, USA).
RNA preparation and GeneChip hybridization
Several micrograms of frozen tissue were sharply dissected from each sample and homogenized with a rotary homogenizer (Omni International) in RNeasy lysis buffer (QIAGEN, Valencia, CA, USA). Total RNA was prepared from tissues and cells using the RNeasy Mini Kit (QIAGEN). Hybridization on oligonucleotide microarrays (U95a GeneChipTM, Affymetrix Incorporated, Santa Clara, CA, USA) was performed as described (Su et al., 2001; Welsh et al., 2001a, b) . GeneChip hybridization data were processed and scaled as described (Su et al., 2001; Welsh et al., 2001a, b) .
Data processing and prefiltering
Microarray data were processed using MAS5.0. (Affymetrix Incorporated, Santa Clara, CA, USA) and scaled to a nominal value of 200 (B3-5 copies of transcript per cell; Lockhart et al., 1996; Wodicka et al., 1997) to facilitate interchip comparison. The primary data have been deposited and is accessible on the Gene Express Omnibus (GEO) server at http://www.ncbi.nlm.-nih.gov/geoc/. The data set was filtered to exclude lowly expressed (o100 fluorescent units) and relatively invariant genes (standard deviation o50 fluorescent units). The filtered data set comprised 5825 probe-sets, corresponding to B5000 unique human genes.
Computational analysis
Supervised learning (KNN) was performed using GeneCluster2 implementing previously described methods (Golub et al., 1999) . k ¼ 3 was used in each case. The optimal performance of supervised prediction was assessed by iterative calculation of the error in each run using 1-20 and 30-100 genes. Agglomerative clustering (average linkage clustering using uncentered correlation) was performed using Cluster (Eisen et al., 1998) and the results visualized using TreeView (Eisen et al., 1998) . SAM was performed as described using a publicly available EXCEL module add-on (Tusher et al., 2001) .
Comparative genomic hybridization
High molecular weight DNA was prepared from frozen samples using standard methods. CGH was performed as described (Arnold et al., 1996) , with minor modifications. Briefly, genomic DNA was labeled with a standard nicklabeling procedure with biotin-16-dUTP (Roche Diagnostics, Mannheim, Germany) for tumor and reference DNA (male), respectively, yielding fragment lengths of 200-2000 bp. Tumor and reference DNA were co-precipitated in the presence of Cot-1 DNA (Life Technologies, Karlsruhe, Germany). The probes were hybridized onto normal male metaphase target slides (Abbott, Wiesbaden, Germany) for 2-3 days in a moist chamber at 371C. Posthybridization washes were performed without formamide (2 Â SSC at RT, 721C and RT for 5 min each). After detection with streptavidin fluorescein isothiocyanate and an antideoxygenin-rhodamine antibody (Roche Diagnostics, Mannheim, Germany) slides were counterstained with DAPI in antifade (Appligene Oncor, Illkrich, France). CGH hybridizations were analysed using a fluorescence microscope connected to a digital imaging system and evaluated with the ISIS-3 software program (MetaSystems, Altlussheim, Germany).
The average number of copy alterations score (ANCA, see text) was calculated separately for G1, G2 and G3 by summing the aberrations (gains and deletions) for each autosome (minimum ANCA: 0 for no alterations; maximum ANCA: 22 if all autosomes show at least one copy number alteration, independent of size (Kiechle et al., 2001) ).
Immunohistochemistry
Ovarian cancer specimens derived from 120 patients presenting to the Department of Gynecology and Obstetrics of the University Hospital of Freiburg, Germany between 1993 and 1998 were included in the immunohistochemical study. TMAs were populated with two to five cylinders of 1 mm diameter tissue from representative areas of formalin-fixed tumors embedded in paraffin blocks and arrayed into a new recipient paraffin block with a custom-built precision instrument (Beecher Instruments, Silver Spring, MD, USA) (MeinholdHeerlein et al., 2001) . Serial sections (4 mm) were applied to 3-aminopropyltriethoxysilane-(Sigma, St Louis, MI, USA) coated slides, as described (Rentrop et al., 1986) . De-waxed tissue sections were immunostained using a diaminobenzidinebased detection method as described in detail, employing either an avidin-biotin complex reagent (Vector Laboratories, Burlingame, CA, USA) (Krajewski et al., 1994) or the Envision-Plus-Horse Radish Peroxidase system (DAKO, Carpinteria, CA, USA) using an automated immunostainer (Dako Universal Staining System) (Krajewski et al., 1999) . Polyclonal antisera specific for S100A2 (DAKO, Carpinteria, CA, USA) and MMP-7 (ABR, Golden, CO, USA) were applied at 1 : 100, 1 : 400, 1 : 5000 (v/v), respectively, while monoclonal antibodies against CD24, MUC-1 and Ep-CAM (NeoMarkers/Labvision, Freemont, CA, USA) at 1 : 200 (v/v) and p21/WAF1 (RD Systems, Minneapolis, MN, USA (Clone 195720)) at 1 : 50. Scorings of immunostained sections were based on the percentage of immunopositive cells (0-100) multiplied by staining intensity (0-3), yielding scores of 0 to 300. Ki-S5 monoclonal antibody (which recognizes a formalinresistant epitope of the Ki-67 proliferation antigen) (Department of Pathology, University of Kiel, Germany) was applied as described (Kreipe et al., 1993) . The Ki-S5 labeling index was calculated as the percentage of positive cells in at least 500 tumor cells. The immunostained slides were evaluated blindly by three independent investigators.
RT-PCR
RT-PCR was carried out exactly as described (Welsh et al., 2001b) , except that the 18s primers (Ambion, Austin, TX, USA) were used to generate 18s products in a separate reaction. Primer pairs were designed for CIRP (NM_001280), c-fos (NM_005252), STAT-1 (NM_007315), IFI-30 (NM_006332), UbcH10 (NM_007019) and cdc20 (NM_001255) using DNASTAR (Madison, WI, USA).
Products were electrophoresed on 2% agarose gels and images captured on an AlphaImager 2200 (Alpha Innotech Corp., San Leandro, CA, USA).
Survival analysis
Kaplan-Meier curves were generated using StatsDirect (Cheshire, UK) and the significance of the curves assessed using log-rank (Mantel-Haenszel) and Wilcoxon's tests.
